Related Experiment Videos
Tenascin immunoreactivity in normal and pathological bone marrow
Y Soini1, D Kamel, M Apaja-Sarkkinen
1Department of Pathology, University of Oulu, Finland.
Insights
Tenascin, a protein found in bone marrow, is present in higher amounts in fibrotic conditions like myelofibrosis. Its presence in various bone marrow diseases suggests a role in their development and as a potential disease marker.
Area of Science:
- Bone Marrow Biology
- Extracellular Matrix Research
- Immunohistochemistry
Background:
- Tenascin is an extracellular matrix glycoprotein implicated in cell growth, adhesion, and tissue remodeling.
- Its role in normal and pathological bone marrow microenvironments requires further elucidation.
Purpose of the Study:
- To investigate the distribution of tenascin within normal and pathological bone marrow samples.
- To correlate tenascin expression with specific bone marrow pathologies and cellular features.
Main Methods:
- Immunohistochemical analysis was performed on 48 distinct bone marrow lesions.
- A monoclonal antibody specific to tenascin was utilized for detection.
Main Results:
- Tenascin immunoreactivity was elevated in bone marrow lesions characterized by increased fibrosis and reticular fibers, notably in myelofibrosis.
- Leukemias exhibited weak to moderate tenascin expression, while hyperplasias showed variable reactivity.
- Normal bone marrow displayed minimal tenascin presence.
Conclusions:
- Tenascin presence correlates with megakaryocytic hyperplasia, potentially mediated by TGF-beta.
- Tenascin may act as a growth promoter or adhesive molecule in the bone marrow.
- The widespread detection of tenascin in bone marrow pathologies suggests its involvement in disease pathogenesis and potential utility as a diagnostic marker.
Aims:
To determine the distribution of tenascin in normal and pathological bone marrow.
Methods:
48 different bone marrow lesions were studied immunohistochemically using a monoclonal antibody to tenascin.
Results:
Tenascin immunoreactivity was found in lesions with increased fibrosis and high numbers of reticular fibres. The strongest immunoreactivity was found in myelofibrosis. Bone marrow from acute and chronic myeloid and lymphatic leukaemias showed weak or moderate immunoreactivity. In hyperplasias inconsistent reticular tenascin immunoreactivity was found; in normal bone marrow, only a few scattered positive fibres were occasionally seen.
Conclusions:
Tenascin was generally observed in conditions in which megakaryocytic hyperplasia was a feature. This is in line with the notion that tenascin synthesis in bone marrow fibroblasts is stimulated by TGF-beta which is synthesised by the megakaryocytic lineage. Tenascin also contains EGF-like repeats. It might therefore function as a growth promoter and in this way could also stimulate synthesis of other matrix components. On the other hand, tenascin could function as an adhesive molecule to some cells of the bone marrow. The presence of tenascin in many pathological states of the bone marrow suggests that it may have a role in their pathogenesis and that it also could be a potential marker of disease.